31 October 2017

This trial is open to pouchitis patients currently in flare that have failed to respond to one or more courses of antibiotics, or are contra-indicated to antibiotics.

Atlantic Healthcare enrols 110th patient to its Phase 3 trial of alicaforsen to treat pouchitis.

Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI) disorders, provides an update that it has recruited its 110th patient, out of a total of 138, to its Phase 3 trial of alicaforsen to treat pouchitis, a rare and serious form of inflammatory bowel disease (IBD) for which there is no approved therapy and limited treatment options. More information from Atlantic Healthcare website

View other News